Serum N-glycan NA3Fb identified as a prognostic biomarker of poor outcome in HBV-related hepatocellular carcinoma
Serum N-glycan profiling represents a promising noninvasive tool for monitoring prognosis and outcomes in HCC patients. Peak 9 (NA3Fb) was identified as a prognostic biomarker significantly associated with clinical outcomes in HBV-related HCC.
Authors
- Pengyuan Kang
- Min Wang
- Lei Xu
- Jie Liu
- Jiang Wang
- Tao Shen
- Siqi Zhong
- Bo Li
- Cuiying Chen
- Xinjie Li
- Rui Lin
- Bo Jiang
Institutions
- Peking University (CN)
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- Viva Biotech (China) (CN)
- Dazhou Central Hospital (CN)
Publication Details
- Journal
- Cancer Cell International
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1186/s12935-025-04100-6
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Chinese Foundation for Hepatitis Prevention and Control
- Southwest Medical University